Variation in adenoma detection rate and the lifetime benefits and cost of colorectal cancer screening: A microsimulation model

JAMA - Journal of the American Medical Association

Volumn 313, Issue 23, 2015, Pages 2349-2358

  Meester, Reinier G S ^a   Doubeni, Chyke A ^b,c   Lansdorp Vogelaar, Iris ^a   Jensen, Christopher D ^d   Van Der Meulen, Miriam P ^a   Levin, Theodore R ^d   Quinn, Virginia P ^e   Schottinger, Joanne E ^e   Zauber, Ann G ^f   Corley, Douglas A ^d   Van Ballegooijen, Marjolein ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d DIVISION OF RESEARCH   (United States)

^e KAISER PERMANENTE   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER THERAPY; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; COMMUNITY SAMPLE; COST BENEFIT ANALYSIS; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; LIFESPAN; MAJOR CLINICAL STUDY; MEDICAL EXAMINATION; MIDDLE AGED; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SIMULATION; VERY ELDERLY; ADENOMA; ADVERSE EFFECTS; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; EARLY DIAGNOSIS; ECONOMICS; MORTALITY; RISK; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

ADENOMA; AGED; AGED, 80 AND OVER; COLONOSCOPY; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; HEALTH CARE COSTS; HUMANS; MIDDLE AGED; MODELS, STATISTICAL; RISK;

EID: 84931046829     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.6251     Document Type: Article

References (40)

1. National Cancer Institute. SEER stat fact sheets: colon and rectum cancer. Accessed September 2014. http://seer.cancer.gov/statfacts/html/colorect.html.
2. Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013;369(12):1095-1105.
3. Doubeni CA, Weinmann S, Adams K, et al. Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. Ann Intern Med. 2013;158(5 Pt 1):312-320.
4. Brenner H, Chang-Claude J, Jansen L, Knebel P, Stock C, Hoffmeister M. Reduced risk of colorectal cancer up to 10 years after screening, surveillance, or diagnostic colonoscopy. Gastroenterology. 2014;146(3):709-717.
5. Van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, Van Deventer SJ, Dekker E. Polypmiss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol. 2006;101(2):343-350.
6. Robertson DJ, Lieberman DA, Winawer SJ, et al. Colorectal cancers soon after colonoscopy: a pooled multicohort analysis. Gut. 2014;63(6):949-956.
7. Farrar WD, Sawhney MS, Nelson DB, Lederle FA, Bond JH. Colorectal cancers found after a complete colonoscopy. Clin Gastroenterol Hepatol. 2006;4(10):1259-1264.
8. Barclay RL, Vicari JJ, Doughty AS, Johanson JF, Greenlaw RL. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. N Engl J Med. 2006;355(24):2533-2541.
9. Adler A, Wegscheider K, Lieberman D, et al. Factors determining the quality of screening colonoscopy: a prospective study on adenoma detection rates, from 12, 134 examinations (Berlin colonoscopy project 3, BECOP-3). Gut. 2013;62(2):236-241.
10. Corley DA, Jensen CD, Marks AR, et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med. 2014;370(14):1298-1306.
11. Austin GL, Fennimore B, Ahnen DJ. Can colonoscopy remain cost-effective for colorectal cancer screening? the impact of practice patterns and the Will Rogers phenomenon on costs. Am J Gastroenterol. 2013;108(3):296-301.
12. US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149(9):627-637.
13. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999;91(5):434-437.
14. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348(9040):1472-1477.
15. Winawer SJ, Zauber AG, Ho MN, et al; The National Polyp StudyWorkgroup. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med. 1993;329(27):1977-1981.
16. Atkin WS, Edwards R, Kralj-Hans I, et al; UK Flexible Sigmoidoscopy Trial Investigators. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375(9726):1624-1633.
17. Rex DK, Ahnen DJ, Baron JA, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012;107(9):1315-1329.
18. Gohel TD, Burke CA, Lankaala P, et al. Polypectomy rate: a surrogate for adenoma detection rate varies by colon segment, gender, and endoscopist. Clin Gastroenterol Hepatol. 2014;12(7):1137-1142.
19. Williams JE, Holub JL, Faigel DO. Polypectomy rate is a valid quality measure for colonoscopy: results from a national endoscopy database. Gastrointest Endosc. 2012;75(3):576-582.
20. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med. 2000;343(3):169-174.
21. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med. 2000;343(3):162-168.
22. Warren JL, Klabunde CN, Mariotto AB, et al Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med. 2009;150(12):849-857.
23. Gatto NM, Frucht H, Sundararajan V, Jacobson JS, Grann VR, Neugut AI. Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst. 2003;95(3):230-236.
24. Zauber AG, Knudsen AB, Rutter CM, et al. Cost-effectiveness of CT Colonography to Screen for Colorectal Cancer. Rockville, MD: Agency for Healthcare Research and Quality; 2007, http://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id52TA.pdf. Accessed May 19, 2015.
25. Leffler DA, Kheraj R, Garud S, et al. The incidence and cost of unexpected hospital use after scheduled outpatient endoscopy. Arch Intern Med. 2010;170(19):1752-1757.
26. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100(9):630-641.
27. Jensen CD, Doubeni CA, Quinn VP, et al. Adjusting for patient demographics has minimal effects on rates of adenoma detection in a large, community-based setting. Clin Gastroenterol Hepatol. 2015;13(4):739-746.
28. US Department of Labor. Bureau of Labor Statistics. 2014; http://www.bls.gov. Accessed January 22, 2014.
29. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR; United States Multi-Society Task Force on Colorectal Cancer. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012;143(3):844-857.
30. Manning WG, Fryback DG, Weinstein MC. Reflecting uncertainty in cost-effectiveness analysis. In: GoldMR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996:247-255.
31. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making. 1985;5(2):157-177.
32. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 5th ed. Philadelphia, PA: Lippincott-Raven; 1997. http://cancerstaging.org/references-tools/deskreferences/Documents/AJCC5thEdCancerStagingManual.pdf.
33. Rex DK, Schoenfeld PS, Cohen J, et al. Quality indicators for colonoscopy. Am J Gastroenterol. 2015;110(1):72-90.
34. Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med. 2010;362(19):1795-1803.
35. Baxter NN, Sutradhar R, Forbes SS, Paszat LF, Saskin R, Rabeneck L. Analysis of administrative data finds endoscopist quality measures associated with postcolonoscopy colorectal cancer. Gastroenterology. 2011;140(1):65-72.
36. Cooper GS, Xu F, Barnholtz Sloan JS, Schluchter MD, Koroukian SM. Prevalence and predictors of interval colorectal cancers in medicare beneficiaries. Cancer. 2012;118(12):3044-3052.
37. Levin B, Lieberman DA, McFarland B, et al; American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134(5):1570-1595.
38. Hewett DG, Rex DK. Improving colonoscopy quality through health-care payment reform. Am J Gastroenterol. 2010;105(9):1925-1933.
39. Ladabaum U, Levin Z, Mannalithara A, Brill JV, Bundorf MK. Colorectal testing utilization and payments in a large cohort of commercially insured US adults. Am J Gastroenterol. 2014;109(10):1513-1525.
40. Sheffield KM, Han Y, Kuo YF, Riall TS, Goodwin JS. Potentially inappropriate screening colonoscopy in Medicare patients: variation by physician and geographic region. JAMA Intern Med. 2013;173(7):542-550.